Healthcare's Missing Intelligence
Monthly Investor Update
"May is the month Saara stopped being a slide deck and started being a business."
The big stuff: we opened our $3M Seed, we won our first enterprise customer in OSH360 — a real one — and we wrapped the pre-seed at $435K, which is a hair over what we set out to raise. The kind of problem we'll happily take all day long.
The runway behind us got us here. The runway ahead is what this letter is for.
$3M at a $7.5M pre-money valuation. Translation: investors put in $3M total; afterward they own about 28.6% of Saara. "Pre-money" is what we're saying Saara is worth before the new money lands. New checks start at $250K. Current pre-seed investors get a friends-and-family bridge at $50K+ at the same valuation — lock in today's price before the OSH360 deal works its way into the next round.
Slightly over the line. The last $100K check tipped us past. We took a victory lap that lasted approximately one cup of coffee, then got back to work.
OSH360 is a fractional "OccHealth" Management firm. Translation: Fortune 15/50/100/500 companies hire them to run on-site and near-site healthcare for their employees — the Amazon Care, Walmart Health, Concentra model. OSH360 picked Saara as their sole operating platform — every clinician, every visit, every report runs on us. Term sheet draft targeted in the next ten days. Flagship clinic in Ohio targets late-Q3 2026 go-live. Credit to Board Director Dr. Anthony Harris for making this introduction.
Why this deal is exciting beyond the dollars. OSH360 is employer-paid — little to no insurance billing, no Medicare paperwork, no payer-mix gymnastics. Their revenue model lives outside the CMS-reimbursement system that ties most healthcare businesses in knots. Clean proof that Saara also works as an operating platform in markets where insurance logic doesn't apply.
Deal structure grows with them, not against them. Hybrid pricing: a platform fee, a per-practitioner fee, and a small per-employee fee tied to OSH360's Fortune 500 client populations. The bigger OSH360 gets, the bigger we get — automatically. We also keep joint IP on the patient-intake module — resellable through our marketplace later.
The pipeline is filling itself. Our Board contributors estimate 10–15 more occupational-health deals like OSH360 are loading up behind it. For the doctors reading: this is like opening a new clinic and getting overbooked in week one. Lovely problem. Also a real problem.
Across every state where current investors live. Translation: every relevant securities regulator has been formally told that Saara is raising money, who is investing, and on what terms. Chris Rogers at Buchalter Law handled it.
We're spending the next one-to-two weeks bug-bashing — running our own product through hell so customers don't have to. Tibou (ex-Apple UX), Hamza Shaikh (Head of Product) and Iruii Favi (ex-Amazon/Meta AI) carried the redesign across the line. It looks clean. It feels calm. That second word is the one we kept aiming for.
Delivered to our engineering partners at Jixi (Mario and Robb):
Saara Studio — the App Store for clinical protocols and the world's first "HealthTech Ecosystem" focusing on care, not tech integrations. OSH360's patient-intake module is the launch product, with a 36-month revenue share as launch partner.
Revenue Integrity — a proprietary, agentic application anchored by our team and the Jixi Team, orchestrated and approved by our Senior Advisory Panel. Our team’s domain depth combined with best-in-class coding, compliance, and AMA CPT® Editorial Panel guidance is the kind of edge no competitor has when building a smarter approach to billing and revenue integrity.
Every clinic operator we know is being squeezed from three sides at once: documentation burden growing, reimbursement not growing with it, and a labor market that isn't coming back to 2019 staffing levels.
The buyer question has shifted from "should we modernize?" to "how fast can we modernize without breaking what currently works?" — and Saara was literally designed to answer the second question.
Employer-paid healthcare models like OSH360's are growing fastest because Fortune 500 HR wants predictable cost and predictable quality. We are sitting exactly where the wave is going.
The OSH360 deal doesn't hit full revenue until Year 2.
During the 90-day onboarding period, we deliberately cut our recurring fees nearly in half to keep incentives lined up while we go live. The structure is correct. It also means our cash situation over the next six months is real, not theoretical.
The Seed pays for three specific things, and all three slip if the Seed doesn't close:
- Customization, security audits (SOC 2 and HITRUST — the two gold-standard certifications enterprise buyers require), and infrastructure OSH360 needs.
- One to two Sales Engineer hires for the current pipeline, with 10–15 additional OccHealth deals loading up behind OSH360.
- Reg D and IP legal work to keep the platform and SEC compliance protected as we scale.
Two specific asks. Both concrete; both actionable; neither is "spread the word."
Warm investor introductions — especially a lead.
A lead investor sets the terms and writes the biggest check. Once we have a lead, the rest of the round fills behind them. Seed checks start at $250K. Current pre-seed investors can write a $50K+ bridge at the same valuation.
Pilot relationships outside occupational health.
Doors into multi-site primary care and specialty groups — the operating problems are identical, but the buying motion is different and we want to start learning it.
This is Issue #1. Going forward, we'll be in your inbox at the end of every month with the same flavor of update — what we won, what we're building, what's stuck, and how you can help. We'll keep the translations in.
Hamza and Iruii built the platform. Dr. Harris, Dr. Cutter, Patrick, and our Senior Advisory Panel built the conditions around it. The fact that all of these names are in one place is, I think, the most underrated competitive advantage Saara has.
Saara is Healthcare's Missing Intelligence — and you are the reason the missing piece is being put in place.
Thank you. Reply with questions, intros, ideas, or arguments. I read every one.
Saara — Issue #1 · May 2026 · For accredited investors only